More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/MS-275 [209783-80-2]
Chemical Structure
Chemical Structure
Chemical Structure

MS-275 [209783-80-2]

Research Use Only
AG-CR1-0032
AdipoGen Life Sciences
CAS Number209783-80-2
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98% (NMR)
Molecular Weight376.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    MS-275 [209783-80-2]
  • Delivery Days Customer
    10
  • CAS Number
    209783-80-2
  • Certification
    Research Use Only
  • Estimated Purity
    >98% (NMR)
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C21H20N4O3
  • Molecular Weight
    376.4
  • Scientific Description
    Chemical. CAS: 209783-80-2. Formula: C21H20N4O3. MW: 376.4. HDAC 1 inhibitor. Antitumor compound. Antiproliferative. TGF-beta type II receptor inducer. Apoptosis inducer. Anti-inflammatory. Angiogenesis inhibitor. Review. Promotes either self-renewal or differentiation of embryonic stem cells. - HDAC 1 inhibitor [1, 2]. Antitumor compound [1-3]. Antiproliferative [2]. TGF-beta type II receptor inducer [2]. Apoptosis inducer [4]. Anti-inflammatory [5]. Angiogenesis inhibitor [6]. Review [7]. Promotes either self-renewal or differentiation of embryonic stem cells [8].
  • SMILES
    NC1=C(NC(=O)C2=CC=C(CNC(=O)OCC3=CC=NC=C3)C=C2)C=CC=C1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors: A. Saito, et al.; PNAS 96, 4592 (1999)
  • MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells: B.I. Lee, et al.; Cancer Res. 61, 931 (2001)
  • MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors: J. Jaboin, et al.; Cancer Res. 62, 6108 (2002)
  • The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1: R.R. Rosato, et al.; Cancer Res. 63, 3637 (2003)
  • MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis: Z.Y. Zhang, et al.; Neuroscience 169, 370 (2010)
  • S-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo: R.K. Srivastava, et al.; Mol. Cancer Ther. 9, 3254 (2010)
  • MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent: H. Hess-Stumpp, et al.; Int. J. Biochem. Cell Biol. 39, 1388 (2007)
  • Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming: A. Kretsovali, et al.; Stem Cells Int. 2012, 1 (2012)